On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges

Abstract

The development of European evidence based guidelines requires a coordinated structure which can be achieved by the integration of an experienced group of methodologists. Nevertheless further improvements are imaginable and might be considered for an update or other European evidence based guidelines.

Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary

“…10) and documented intolerance or contraindication of standard systemic treatments. Hungarian Guideline on Psoriasis Therapies is based on and synchronized with the European S3 Psoriasis Guideline in accordance with the financing protocol of the NHIF (13).…”

The Protective Effect of Adalimumab on Renal Injury in a Model of Abdominal Aorta Cross-Clamping

“…Studies of ADA treatment in rats are limited. It was reported that the highest serum level of ADA could be achieved after of 5 days of subcutaneous administration [36]. In this study we administered ADA intraperitoneally 5 days before giving I/R and demonstrated that it was protective in I/R.…”

Safety of Biological Preparations and Small Molecules. Are There Any Differences?

“…That is why it is more difficult to reveal the cause-effect relation [6][7][8]17]. It is also important that it is not always possible to track these phenomena through time, namely, efficacy [effect obtained in "ideal conditions" of randomized placebo-controlled trials (RCT)].…”

“…Areas of use of them are extremely versatile: endocrinology, oncology, rheumatology, oncohematology and hematology. The modern leaders in the group of BP are monoclonal antibodies to various receptors, enzymes and macroorganism's cells [6][7][8][9][10][11]:…”